Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Complarate vs Actemra in Healthy Volunteers
NCT06488521Phase 1Completed
- Sponsor
- Generium
- Start
- Jun 2024
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Generium. Primary endpoints: Area under the plasma concentration versus time curve at Day 43 and Peak Plasma Concentration at Day 43. Started Jun 2024; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06488521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488521.